Entellus Medical Inc. (NASDAQ:ENTL)’s share price dropped 7.3% on Tuesday . The company traded as low as $18.48 and last traded at $18.53, with a volume of 62,454 shares traded. The stock had previously closed at $19.98.

ENTL has been the topic of a number of recent analyst reports. BTIG Research reaffirmed a “buy” rating on shares of Entellus Medical in a research note on Wednesday, June 29th. Canaccord Genuity reaffirmed a “buy” rating and set a $23.00 price target on shares of Entellus Medical in a research note on Wednesday, June 29th. Finally, Zacks Investment Research downgraded shares of Entellus Medical from a “hold” rating to a “sell” rating in a research note on Thursday, April 14th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $23.80.

The company’s 50-day moving average price is $17.98 and its 200 day moving average price is $16.76. The firm’s market cap is $341.92 million.

Entellus Medical (NASDAQ:ENTL) last released its earnings results on Wednesday, May 4th. The medical technology company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.10. The firm earned $16.90 million during the quarter, compared to analysts’ expectations of $16.34 million. The business’s revenue was up 25.2% on a year-over-year basis. During the same period last year, the business earned ($0.35) earnings per share. On average, analysts forecast that Entellus Medical Inc. will post ($1.32) earnings per share for the current year.

An institutional investor recently raised its position in Entellus Medical stock. Wells Fargo & Company MN boosted its stake in Entellus Medical Inc. (NASDAQ:ENTL) by 7.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 464,550 shares of the medical technology company’s stock after buying an additional 31,082 shares during the period. Wells Fargo & Company MN owned 2.47% of Entellus Medical worth $7,832,000 as of its most recent SEC filing.

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses.